Angiotensin-converting enzyme 2 protects from severe acute lung failure.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study
PubMed 16001071 · doi:10.1038/nature03712
What was done
The authors evaluated the role of renin-angiotensin system components (ACE, ACE2, AT1a, and AT2 receptors) in mouse models of severe acute lung injury induced by acid aspiration or sepsis, using genetic knockouts (including Ace-deficient mice) and recombinant ACE2 administration.
What was found
No numerical values or effect sizes are reported in the abstract. ACE2 and the AT2 receptor protected mice from severe acute lung injury, whereas ACE, angiotensin II, and the AT1a receptor promoted disease pathogenesis, induced lung edema, and impaired lung function. Mice deficient in Ace showed markedly improved disease, and treatment with recombinant ACE2 protected mice from severe acute lung injury.
Why it matters
This study demonstrates a protective counter-regulatory role for ACE2 against angiotensin II-mediated acute lung injury in preclinical models, suggesting recombinant ACE2 as a potential therapeutic strategy for ARDS.
Limits
Findings are limited strictly to mouse models of ARDS, which may not fully reflect human disease. The abstract does not report sample sizes, specific quantitative measurements, effect sizes, or statistical confidence intervals.
Cited by
- supports SARS-CoV-1 binds to ACE2, internalizes the receptor, downregulates ACE2 expression, and worsens acute lung injury.